K Number
K990972
Device Name
HP VIRIDIA COMPONENT MONITORING SYSTEM, HP VIRIDIA CMS 24/26, HP VIRIDIA MULTI-MEASUREMENT SERVER AND COMPACT PORTABLE T
Date Cleared
1999-04-19

(27 days)

Product Code
Regulation Number
870.1025
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The Hewlett-Packard family of patient monitor products is intended for monitoring, recording, and alarming of multiple physiological parameters. The devices are indicated for use in health care facilities by health care professionals whenever there is a need for monitoring the physiological parameters of adult, neonatal, and pediatric patients.
Device Description
The name of this device is the Hewlett-Packard family of Viridia Patient Monitors individually known as the M1175A/76A/77A (Viridia CMS), the M1205A (Viridia 24/26), and the M3000A/M3046A (Viridia M3/4). The common name is patient monitor. The modification is a software based change that involves only the SpO2 algorithm of the measurement computer processing unit of each device.
More Information

Not Found

No
The summary describes a software modification to an existing SpO2 algorithm and mentions standard performance testing and clinical evaluations, but there is no mention of AI, ML, or related concepts.

No
The description states the device is "intended for monitoring, recording, and alarming of multiple physiological parameters," which indicates a diagnostic or monitoring function, not a therapeutic one.

Yes

Explanation: The "Intended Use/Indications for Use" section explicitly states that the device is intended for "monitoring, recording, and alarming of multiple physiological parameters." Monitoring vital signs and physiological parameters is a key function of diagnostic devices, as it helps healthcare professionals assess a patient's condition for diagnostic purposes.

No

The device is described as a modification to existing patient monitors (hardware devices) and the performance studies include hardware testing, indicating it is not solely software.

Based on the provided information, this device is not an In Vitro Diagnostic (IVD).

Here's why:

  • Intended Use: The intended use is for "monitoring, recording, and alarming of multiple physiological parameters." This involves directly measuring physiological signals from the patient's body (like heart rate, blood pressure, oxygen saturation via SpO2).
  • IVD Definition: IVDs are defined as devices intended for use in the examination of specimens derived from the human body (such as blood, urine, tissue) to provide information for diagnostic, monitoring, or compatibility purposes.
  • Device Description: The device is a "patient monitor" that measures physiological parameters. The modification is to the SpO2 algorithm, which processes a signal obtained directly from the patient's body (likely via a sensor on the finger or earlobe).
  • Lack of Specimen Handling: There is no mention of collecting or analyzing specimens from the patient.

The device is a patient monitor that measures physiological parameters in vivo (within the living body), not in vitro (in glass or outside the body using specimens).

N/A

Intended Use / Indications for Use

The Hewlett-Packard family of patient monitor products is intended for monitoring, recording, use and alarming of multiple physiological parameters. The devices are indicated for use in health care facilities by health care professionals whenever there is a need for monitoring the physiological parameters of adult, neonatal, and pediatric patients.

Product codes

74 DSI

Device Description

The modification is a software based change that involves only the SpO2 algorithm of the measurement computer processing unit of each device.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

adult, pediatric, and neonatal patients.

Intended User / Care Setting

health care facilities by health care professionals

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Clinical performance evaluations using the new algorithm were conducted with ICU neonates to validate the measurement of oxygen saturation, and with adults, for the purpose of validating accuracy by conducting a desaturation study with co-oximeters as a reference.

Summary of Performance Studies

Verification, validation, and testing activities were conducted to establish the performance and reliability characteristics of the new SpO2 algorithm using neonatal and adult patient data. Testing involved system level tests, integration tests, safety testing from hazard analysis, interference testing, and hardware testing. Pass/Fail criteria were based on the specifications cleared for the predicate devices and test results showed substantial equivalence.

Clinical performance evaluations using the new algorithm were conducted with ICU neonates to validate the measurement of oxygen saturation, and with adults, for the purpose of validating accuracy by conducting a desaturation study with co-oximeters as a reference. All tested sensor-monitor combinations passed test criteria and test results showed substantial equivalence. No adverse events occurred during the studies.

Key Metrics

Not Found

Predicate Device(s)

K971910, K981576, K990125, K903523, and K923343

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 870.1025 Arrhythmia detector and alarm (including ST-segment measurement and alarm).

(a)
Identification. The arrhythmia detector and alarm device monitors an electrocardiogram and is designed to produce a visible or audible signal or alarm when atrial or ventricular arrhythmia, such as premature contraction or ventricular fibrillation, occurs.(b)
Classification. Class II (special controls). The guidance document entitled “Class II Special Controls Guidance Document: Arrhythmia Detector and Alarm” will serve as the special control. See § 870.1 for the availability of this guidance document.

0

K 990972

4/19/99

10.0 510(k) Summary

This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of the Safe Medical Devices Act of 1990 and 21 C.F.R. §807.92.

  1. The submitter of this premarket notification is: Egon Pfeil Regulatory Affairs Medical Products Group-Europe Hewlett-Packard GmbH Herrenberger Strasse 110-140 D-71034 Germany Tel: 011 49 (7031) 14-2243 011 49 (7031) 14-4297 Fax: Email:egon pfeil@hp.com

This summary was prepared on March 11, 1999

    1. The name of this device is the Hewlett-Packard family of Viridia Patient Monitors individually known as the M1175A/76A/77A (Viridia CMS), the M1205A (Viridia 24/26), and the M3000A/M3046A (Viridia The common name is patient monitor. Classification names are M3/4) . . as follows:

| Regulation

NumberClassification Name
870.2700Oximeter
870.2710Ear Oximeter
870.1435Computer, Diagnostic, Pre-Programmed, Single-Function
870.1025Detector and Alarm, Arrythmia
870.2900Cable, Transducer and Electrode, Patient (including connector)
  • The new combination device is substantially equivalent to previously 3. cleared HP devices marketed pursuant to K971910, K981576 and K990125, K903523, and K923343.
    1. The modification is a software based change that involves only the SpO2 algorithm of the measurement computer processing unit of each device.
    1. The new device has the same intended use as the legally marketed predicate devices. When used in the hospital environment or mobile environment for patient transport monitoring, the device is intended for measuring and displaying, recording and alarming multiple physiological parameters and waves in adult, pediatric, and neonatal patients.

1

    1. The new combination device has the same technological characteristics as the legally marketed predicate devices.
    1. Verification, validation, and testing activities were conducted to establish the performance and reliability characteristics of the new SpO2 algorithm using neonatal and adult patient data. Testing involved system level tests, integration tests, safety testing from hazard analysis, interference testing, and hardware testing. Pass/Fail criteria were based on the specifications cleared for the predicate devices and test results showed substantial equivalence.

Clinical performance evaluations using the new algorithm were conducted with ICU neonates to validate the measurement of oxygen saturation, and with adults, for the purpose of validating accuracy by conducting a desaturation study with co-oximeters as a reference. All tested sensor-monitor combinations passed test criteria and test results showed substantial equivalence. No adverse events occurred during the studies.

2

Image /page/2/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized image of an eagle with three lines representing its wings. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

APR 1 9 1999

Mr. Egon Pfeil Medical Products Group-Europe Hewlett-Packard GmbH Herrenberger Strasse 110-140 Boeblingen, Germany 71034

Re: K990972 Viridia Component Monitoring System M1175A/76A/77A and Viridia 24/26 M1205A Rev.K and The Viridia HP M3000A/M3056A, Rev.B Patient Monitors Requlatory Class: III (three) Product Code: 74 DSI Dated: March 20, 1999 Received: March 23, 1999

Dear Mr. Pfeil:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in requlatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

3

Page 2 - Mr. Egon Pfeil

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Thomas J. Callahan

Thomas J. Callahan, Ph.D. Director Division of Cardiovascular, Respiratory, and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

4

3.1 ODE Indications Statement

Indications for Use Statement

510 (k) Number

(if known)

  • The Hewlett-Packard Company (HP) family of Device Name Viridia patient monitors. These devices are individually known as the Viridia Component Monitoring System M1175A, M1176A, M1177A /Viridia 24/26 M1205A Rev.K, and the Viridia HP M3000A/M3046A Patient Monitor Rev.B.
    • The Hewlett-Packard family of patient monitor Indications for products is intended for monitoring, recording, use and alarming of multiple physiological parameters. The devices are indicated for use in health care facilities by health care professionals whenever there is a need for monitoring the physiological parameters of adult, neonatal, and pediatric patients.

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED

Concurrence of CDRH, Office of Device Evaluation (ODE)

Ath. A. Garlouski.

Division Sign-Off) Division of Cardiovascular, Respiratory, and Neurological Devices

510(k) Number__

Prescription Use X
(Per 21 CFR 801.109)

OR

Over-The-Counter Use